Faculty

Institution

Unit

Venue

Kanishka Sircar

Professor Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Pathology And Genomic Medicine

Department Of Surgical Pathology

The University of Texas MD Anderson Cancer Center

Kanishka Sircar is a Professor at The University of Texas MD Anderson Cancer Center, specializing in surgical oncology and urology. His research focuses on genitourinary cancers, particularly kidney cancer, with recent work on prognostic biomarkers (KIM-1, circulating tumor DNA) for oligometastatic clear-cell renal cell carcinoma, the K-COMPASS model, and therapeutic targets like TRIP13 in chromophobe renal cell carcinoma. He has published in The Lancet Oncology, Nature Communications, and Cancer Research, and contributed to NCCN Guidelines for testicular cancer.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Kanishka Sircar

The University of Texas MD Anderson Cancer Center

Professor Associate Professor

You can click a keyword to filter the displayed items

urology oncology kidney cancer genitourinary cancers cancer research pathology tumor biology cancer care metastasis radiation oncology surgical oncology cancer treatment oncogenes prostate cancer medicinal research nephrology cancer cells molecular cancer cancer discovery jama oncology surgical pathology cancer biology cancer genomics neurology carcinogenesis cancer genetics renal cell carcinoma cancer imaging histopathology cancer letter molecular diagnostics cellular therapy pharmacotherapy kidney research sarcomatoid dedifferentiation thoracic oncology cancer management tumor heterogeneity tumoral pathology tumor targeting immune checkpoint inhibitors renal medullary carcinoma adrenal disease adrenocortical carcinoma clinical pathology anti-cancer agents clinical mycology prostatic disease systemic therapy endocrine oncology randomized controlled trials kidney failure prognostic biomarkers cancer growth testicular cancer clinical outcomes renal pathophysiology malignant disease liver cancer prognostic evaluation oncologic imaging clinical evidence molecular pathology hematological malignancies cancer risk kidney transplantation castration-resistant prostate cancer immunosuppressive tumor microenvironment clinical practice guidelines axl overcomes resistance tertiary care center upper urinary tract tumour necrosis aggressive biology urothelial carcinoma chemosensitive cancer personalized medicine lung cancer cancer immunotherapy medicine cell biology biostatistics pharmacology therapeutic targets biomarkers biomedical informatics sarcoma systems biology bladder cancer future medicinal chemistry tumor microenvironment drug discovery clinical biochemistry clinical proteomics translational medicine individualized medicine molecular medicine gynecologic oncology pharmacological research experimental medicine translational research

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract Pr009: Spatial Single-Cell Transcriptomics Reveal Targetable Macrophage Subsets Associated With Antiangiogenic Therapy Resistance in Renal Cell Carcinoma. Cancer Research (2026)

Circulating Kim-1 and Ctdna as Prognostic Markers in Oligometastatic Clear Cell Renal Cell Carcinoma (Ccrcc): The K-Compass Model.. Journal of Clinical Oncology (2026)

pathologyurologykidney cancermolecular canceroncogenesgenitourinary cancerscancer researchoncologycancer genomicsk-compass modeltumor biologyprognostic biomarkersprognostic markerscancer cellsmolecular diagnostics

Ip84-06 Deregulation of Spindle Assembly Checkpoints via Trip13 Upregulation Leads to Loss of Heterozygosity in Aggressive Chromophobe Renal Cell Carcinoma and May Be a Promising Therapeutic Target. The Journal of Urology (2026)

urologykidney cancermolecular cell biologyoncogenesgenitourinary cancersmolecular biologycancer geneticstumor biologycarcinogenesiscell biology

Kim-1 and Circulating Tumor Dna Are Prognostic Markers for Oligometastatic Clear-Cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model. European Urology (2026)

pathologyurologykidney cancergenitourinary cancerscancer researchoncologytumor heterogeneitycancer genomicscancer discoverymultivariable prognostic modeltumor biologyprognostic biomarkersmolecular diagnosticsjama oncology

770 Adult’s Wilms Tumor: Twenty-Year Experience of a Tertiary Cancer Center With Clinicopathological and Molecular Annotation. Laboratory Investigation (2025)

pathologyanatomical pathologysurgical pathologycancer researchoncologytertiary cancer centerwilms tumormolecular annotation

7Phase 2 Trial of Metastasis Directed Radiotherapy Without Systemic Therapy (Mrws) for Oligometastatic Clear Cell Renal Cell Carcinoma (Ccrcc) and Investigation of Circulating Tumor Dna (Ctdna). The Oncologist (2025)

urologykidney cancercancer treatmenttumor dnagenitourinary cancerscancer researchoncologyradiation oncologysurgical oncologymetastasisradiation therapyjama oncologysystemic therapy

925 Primary Adenocarcinoma of the Urethra: A Clinicopathologic Study of 48 Cases. Laboratory Investigation (2025)

pathologyurologyanatomical pathologysurgical pathologygenitourinary cancersurogynecologybladder cancerclinicopathologic studyprimary adenocarcinomaurological research

Abstract 3971: Single-Cell Transcriptomic Insights Into Tumor and Immune Dynamics Driving Resistance to Sitravatinib, Nivolumab, and Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma. Cancer Research (2025)

cancer immunotherapykidney cancersingle-cell analysiscancer cellssingle-cell transcriptomic insightsoncogenestumor microenvironmentimmune dynamicssingle cell sequencingsystems biologyimmunologyimmune checkpoint inhibitorscell biologyabstract 3971

Abstract Ct132: Phase 2 Trial of Metastasis Directed Radiotherapy Without Systemic Therapy (Mrws) for Oligometastatic Clear Cell Renal Cell Carcinoma (Ccrcc) and Investigation of Circulating Tumor Dna (Ctdna) as a Personalized Biomarker. Cancer Research (2025)

urologykidney cancercancer imagingcancer treatmentgenitourinary cancersphase 2oncologyradiation oncologysurgical oncologymetastasisabstract ct132personalized biomarkerjama oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Metastatic Variant Histology (Non-Clear Cell) Renal Cell Carcinoma. Journal for ImmunoTherapy of Cancer (2025)

urologykidney cancercancer treatmentmedicinegenitourinary cancersoncologynon-clear cellmetastasispharmacotherapymetastatic variant histologyimmune checkpoint inhibitorscancer carerenal cell carcinoma

1
2
3
4
5
15
10 / page

Kanishka Sircar

Professor Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Pathology And Genomic Medicine

Department Of Surgical Pathology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Kanishka Sircar

The University of Texas MD Anderson Cancer Center

Professor Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract Pr009: Spatial Single-Cell Transcriptomics Reveal Targetable Macrophage Subsets Associated With Antiangiogenic Therapy Resistance in Renal Cell Carcinoma. Cancer Research (2026)

Circulating Kim-1 and Ctdna as Prognostic Markers in Oligometastatic Clear Cell Renal Cell Carcinoma (Ccrcc): The K-Compass Model.. Journal of Clinical Oncology (2026)

urologykidney cancermolecular cell biologyoncogenesgenitourinary cancersmolecular biologycancer geneticstumor biologycarcinogenesiscell biology

Kim-1 and Circulating Tumor Dna Are Prognostic Markers for Oligometastatic Clear-Cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model. European Urology (2026)

770 Adult’s Wilms Tumor: Twenty-Year Experience of a Tertiary Cancer Center With Clinicopathological and Molecular Annotation. Laboratory Investigation (2025)

pathologyanatomical pathologysurgical pathologycancer researchoncologytertiary cancer centerwilms tumormolecular annotation

urologykidney cancercancer treatmenttumor dnagenitourinary cancerscancer researchoncologyradiation oncologysurgical oncologymetastasisradiation therapyjama oncologysystemic therapy

925 Primary Adenocarcinoma of the Urethra: A Clinicopathologic Study of 48 Cases. Laboratory Investigation (2025)

pathologyurologyanatomical pathologysurgical pathologygenitourinary cancersurogynecologybladder cancerclinicopathologic studyprimary adenocarcinomaurological research

urologykidney cancercancer imagingcancer treatmentgenitourinary cancersphase 2oncologyradiation oncologysurgical oncologymetastasisabstract ct132personalized biomarkerjama oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Metastatic Variant Histology (Non-Clear Cell) Renal Cell Carcinoma. Journal for ImmunoTherapy of Cancer (2025)

urologykidney cancercancer treatmentmedicinegenitourinary cancersoncologynon-clear cellmetastasispharmacotherapymetastatic variant histologyimmune checkpoint inhibitorscancer carerenal cell carcinoma

1
2
3
4
5
15
10 / page